The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
October 1992
in “The New England Journal of Medicine”
TLDR Finasteride effectively treats BPH but may increase sexual dysfunction risk.
The study evaluated the effect of finasteride on men with benign prostatic hyperplasia (BPH). Finasteride inhibits the enzyme 5a-reductase, which prevents the conversion of testosterone to dihydrotestosterone, the androgen responsible for prostatic growth and enlargement. The study found that men treated with 5 mg of finasteride per day had a significant decrease in urinary symptoms, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction. The study concluded that finasteride is an effective treatment for BPH.
View this study on nejm.org →
Cited in this study
research The clinical development of a 5α-reductase inhibitor, finasteride
Finasteride effectively treats BPH, but needs more trials to understand potential.
research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*
Finasteride safely lowers DHT levels without affecting testosterone.
Related
research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Finasteride effectively treats BPH but may increase sexual dysfunction risk.
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.
Finasteride doesn't affect hormone levels in normal men.
research The clinical development of a 5α-reductase inhibitor, finasteride
Finasteride effectively treats BPH, but needs more trials to understand potential.